ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
Panelists discuss how the AURIGA trial demonstrates superior outcomes with daratumumab plus lenalidomide maintenance compared with lenalidomide alone after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma while examining key subgroup analyses that inform treatment decisions regarding posttransplant maintenance therapy selection.
Video content above is prompted by the following:
- For patients who have received ASCT, please comment on the latest data from the AURIGA trial, evaluating daratumumab plus lenalidomide maintenance in NDMM.
- AURIGA trial, subgroup analysis
- How does the data impact your choice of subsequent treatment, post induction therapy?
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
